If you do not wish to accept any of the cookies on this site, click here Privacy Policy How Sensilab Protects Your Data Last updated: 2026-05-27 The protection of your personal data is an issue we take very seriously
J Immunol, 146: 1163-1168
Clinical Evidence: Retatrutide's Impressive Results In a recent phase 2 trial for obesity, retatrutide demonstrated remarkable efficacy: Up to 24.2% weight loss at 48 weeks with the highest dose, surpassing the weight loss seen with both semaglutide (15-17%) and tirzepatide (22.5%) at their respective highest doses
88,89,90 Based on this mechanism, researchers have designed siRNAs that target specific pathological genes to achieve specific gene silencing using RNAi
The development of gut hormone dual- and triagonists holds promise for treating obesity and T2DM with a level of effectiveness comparable to bariatric surgery
We utilize FDA-approved medications such as Wegovy and Zepbound to support your weight loss efforts
)
